Talking Medicines are delighted to be showcased in the SIS Ventures inaugural Impact Report, sharing space with an incredible portfolio of companies. Our journey, commitment, and progress underscore the impactful strides we’ve taken alongside the SIS Ventures team.
” The SIS Ventures team has supported us to ensure that the impact thesis remains relevant to growth. We have seen that customers are increasingly interested to understand Talking Medicines’ values, including its commitment to impact – this is aligned to growth goals and is part of their assessment of whether to work with the company. We feel that we are in a strong position that SIS Ventures has helped us reach. ” – Dr Scott Crae, Co-founder, Talking Medicines.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams. The Talking Medicines mission is to be the World’s Gold Standard for Patient Intelligence by Medicine.
